Literature DB >> 27263465

The Dual Roles of NRF2 in Cancer.

Silvia Menegon1, Amedeo Columbano2, Silvia Giordano3.   

Abstract

NRF2 has been traditionally considered as a tumor suppressor because its cytoprotective functions are deemed to be the main cellular defense mechanism against exogenous and endogenous insults, including xenobiotics and oxidative stress. However, several recent studies demonstrate that hyperactivation of the NRF2 pathway creates an environment that favors the survival of normal as well as malignant cells, protecting them against oxidative stress, chemotherapeutic agents, and radiotherapy. In a rapidly advancing field, this review summarizes some of the known mechanisms by which NRF2 can exert its oncogenic functions, and describes the current status of NRF2 inhibitors, providing a clear rationale for the consideration of NRF2 as a powerful putative therapeutic target in cancer treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  KEAP1; NRF2; antioxidant response; mutations

Mesh:

Substances:

Year:  2016        PMID: 27263465     DOI: 10.1016/j.molmed.2016.05.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  188 in total

Review 1.  Mitochondria-Centric Review of Polyphenol Bioactivity in Cancer Models.

Authors:  Jan F Stevens; Johana S Revel; Claudia S Maier
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

2.  Gene expression analysis in peripheral blood cells of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): identification of NRF2 pathway activation.

Authors:  Carolina Arenas Valencia; Liliana Lopez Kleine; Andres M Pinzon Velasco; Andrea Y Cardona Barreto; Clara E Arteaga Diaz
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

3.  β-TrCP1 Is a Vacillatory Regulator of Wnt Signaling.

Authors:  Marcus John Long; Hong-Yu Lin; Saba Parvez; Yi Zhao; Jesse Richard Poganik; Paul Huang; Yimon Aye
Journal:  Cell Chem Biol       Date:  2017-07-20       Impact factor: 8.116

4.  Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.

Authors:  Kamil Lisek; Dawid Walerych; Giannino Del Sal
Journal:  Mol Cell Oncol       Date:  2016-09-02

5.  Keap1/Nrf2 impairing revised: are we missing the single nucleotide polymorphisms?

Authors:  Lucia Anna Muscarella; Vito Michele Fazio
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.

Authors:  E-J Choi; B-J Jung; S-H Lee; H-S Yoo; E-A Shin; H-J Ko; S Chang; S-Y Kim; S-M Jeon
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 7.  p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Authors:  Koji Taniguchi; Shinichiro Yamachika; Feng He; Michael Karin
Journal:  FEBS Lett       Date:  2016-08-06       Impact factor: 4.124

8.  The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.

Authors:  Shu Zhang; Jie Zhang; Katja Evert; Xiaolei Li; Pin Liu; Andras Kiss; Zsuzsa Schaff; Cindy Ament; Yi Zhang; Monica Serra; Matthias Evert; Nianyong Chen; Feng Xu; Xin Chen; Junyan Tao; Diego F Calvisi; Antonio Cigliano
Journal:  Am J Pathol       Date:  2020-04-10       Impact factor: 4.307

9.  Chaperone-Mediated Autophagy Promotes Beclin1 Degradation in Persistently Infected Hepatitis C Virus Cell Culture.

Authors:  Yucel Aydin; Christopher M Stephens; Srinivas Chava; Zahra Heidari; Rajesh Panigrahi; Donkita D Williams; Kylar Wiltz; Antoinette Bell; Wallace Wilson; Krzysztof Reiss; Srikanta Dash
Journal:  Am J Pathol       Date:  2018-08-01       Impact factor: 4.307

10.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.